1. Home
  2. BOH vs IBRX Comparison

BOH vs IBRX Comparison

Compare BOH & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOH
  • IBRX
  • Stock Information
  • Founded
  • BOH 1897
  • IBRX 2014
  • Country
  • BOH United States
  • IBRX United States
  • Employees
  • BOH N/A
  • IBRX N/A
  • Industry
  • BOH Major Banks
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BOH Finance
  • IBRX Health Care
  • Exchange
  • BOH Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • BOH 2.8B
  • IBRX 2.4B
  • IPO Year
  • BOH N/A
  • IBRX N/A
  • Fundamental
  • Price
  • BOH $65.11
  • IBRX $2.87
  • Analyst Decision
  • BOH Hold
  • IBRX Strong Buy
  • Analyst Count
  • BOH 6
  • IBRX 5
  • Target Price
  • BOH $71.67
  • IBRX $11.40
  • AVG Volume (30 Days)
  • BOH 278.0K
  • IBRX 10.1M
  • Earning Date
  • BOH 07-21-2025
  • IBRX 08-11-2025
  • Dividend Yield
  • BOH 4.30%
  • IBRX N/A
  • EPS Growth
  • BOH N/A
  • IBRX N/A
  • EPS
  • BOH 3.56
  • IBRX N/A
  • Revenue
  • BOH $640,351,000.00
  • IBRX $31,222,000.00
  • Revenue This Year
  • BOH $15.73
  • IBRX $567.98
  • Revenue Next Year
  • BOH $7.97
  • IBRX $160.56
  • P/E Ratio
  • BOH $18.28
  • IBRX N/A
  • Revenue Growth
  • BOH N/A
  • IBRX 10238.41
  • 52 Week Low
  • BOH $55.43
  • IBRX $1.83
  • 52 Week High
  • BOH $82.70
  • IBRX $7.63
  • Technical
  • Relative Strength Index (RSI)
  • BOH 41.53
  • IBRX 49.40
  • Support Level
  • BOH $64.30
  • IBRX $2.77
  • Resistance Level
  • BOH $66.40
  • IBRX $3.24
  • Average True Range (ATR)
  • BOH 1.22
  • IBRX 0.23
  • MACD
  • BOH -0.23
  • IBRX -0.03
  • Stochastic Oscillator
  • BOH 17.20
  • IBRX 19.74

About BOH Bank of Hawaii Corporation

Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: